Home/Pipeline/Stem cell-derived pancreatic endocrine cell clusters

Stem cell-derived pancreatic endocrine cell clusters

Type 1 Diabetes

Pre-clinicalActive

Key Facts

Indication

Type 1 Diabetes

Phase

Pre-clinical

Status

Active

Company

Seraxis

About Seraxis

Seraxis is a private, clinical-stage biotech focused on a stem cell-derived islet replacement therapy for Type 1 Diabetes. Its core technology is based on a proprietary, engineered stem cell line designed to produce pure, potent, and immunologically compatible pancreatic endocrine cells. The company is advancing its lead program toward clinical trials and is actively seeking strategic partnerships to accelerate development and broaden the application of its platform.

View full company profile

Therapeutic Areas

Type 1 Diabetes Metabolic Diseases

Other Type 1 Diabetes Drugs

Drug	Company	Phase	Status
eRapa	Biodexa Pharmaceuticals	Preclinical	Research
ImmCelz™	Creative Medical Technology Holdings	Clinical Trial	Active
Adimune (ADi-001/002)	Aditxt	Preclinical / Early Clinical	Active
MSC‑Diabetes	Advancells	Phase 1	Active
BioChaperone® Lispro (THDB0206)	Adocia	Phase 3	Active
AdoShell® Islet Cell Therapy	Adocia	Preclinical	Platform Development
Pediatric Indications (<2 years)	Tandem Diabetes	Research	Exploratory
Icovamenib (BMF-219)	Biomea Fusion	Phase 2	Completed Follow-up, Data Pending
Undisclosed Novel Strategy	CG Scientific	Pre-clinical	Early Research
Sotagliflozin	Lexicon Pharmaceuticals	Phase 3	Regulatory Path Uncertain
Stem Cell-Derived Beta Cells	BioTalentum	Pre-clinical	Active
NICHE	Continuity Biosciences	Pre-clinical	Active